|
Market Closed -
Nasdaq
01:30:00 26/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 26.92 USD | +2.47% |
|
+6.07% | -7.30% |
| 17/09 | Arcutis Biotherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:50 PM | |
| 25/08 | Oruka Therapeutics Names Chief Commercial Officer | MT |
| Market Cap | 338.36Cr 296.91Cr 280.42Cr 255.55Cr 478.38Cr 32TCr 481.79Cr 3.36TCr 1.3TCr 17TCr 1.27TCr 1.24TCr 53TCr | P/E 2026 * |
67x | P/E 2027 * | 20.8x |
|---|---|---|---|---|---|
| Enterprise Value | 309.52Cr 271.61Cr 256.52Cr 233.77Cr 437.61Cr 30TCr 440.73Cr 3.07TCr 1.19TCr 15TCr 1.16TCr 1.14TCr 49TCr | EV / Sales 2026 * |
5.76x | EV / Sales 2027 * | 4x |
| Free-Float |
98.23% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ARQT | Delayed | |
CBOE
| ARQT | Real-time |
Last Transcript: Arcutis Biotherapeutics, Inc.
| 1 day | +2.47% | ||
| 1 week | +6.07% | ||
| Current month | +12.31% | ||
| 1 month | +7.08% | ||
| 3 months | -0.30% | ||
| 6 months | +20.29% | ||
| Current year | -7.30% |
| 1 week | 25.19 |  | 28.29 |
| 1 month | 23.1 | | 28.29 |
| Current year | 19.3 | | 30.75 |
| 1 year | 17.67 | | 31.77 |
| 3 years | 1.76 | | 31.77 |
| 5 years | 1.76 | | 31.77 |
| 10 years | 1.76 | | 40.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Todd Watanabe
CEO | Chief Executive Officer | 58 | 01/04/2017 |
| Corporate Officer/Principal | 71 | 03/12/2025 | |
Latha Vairavan
DFI | Director of Finance/CFO | - | 15/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Patrick Heron
CHM | Chairman | 55 | 01/12/2019 |
Todd Watanabe
BRD | Director/Board Member | 58 | 01/01/2016 |
Howard Welgus
BRD | Director/Board Member | 74 | 01/08/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/09/26 | Sell | General Counsel | -3,674 | 0.0029% | ||
| 15/09/26 | Exercice | Director | 12,922 | 0.0103% | ||
| 08/09/26 | Sell | General Counsel | -9,989 | 0.0079% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.47% | +6.07% | +53.22% | +361.75% | 338.36Cr | |
| +2.08% | +29.11% | +712.09% | +102.69% | 7.94TCr | |
| -1.00% | +0.41% | +39.75% | -5.33% | 7.87TCr | |
| -1.21% | +0.77% | -8.90% | -30.77% | 5.95TCr | |
| +1.18% | +3.03% | +8.89% | +167.27% | 4.66TCr | |
| -1.80% | -2.29% | -11.16% | +30.65% | 4.65TCr | |
| +0.55% | +5.61% | +65.68% | -11.80% | 3.36TCr | |
| -0.44% | -1.13% | +49.81% | +108.99% | 2.51TCr | |
| -0.10% | +3.21% | +6.92% | +160.99% | 2.21TCr | |
| +0.05% | -2.42% | +60.01% | +97.55% | 1.53TCr | |
| Average | +0.18% | +4.25% | +97.63% | +98.20% | 4.1TCr | |
| Weighted average by Cap. | +0.00% | +6.45% | +155.37% | +57.87% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54Cr 47Cr 45Cr 41Cr 76Cr 5.15TCr 77Cr 532.9Cr 206.4Cr 2.63TCr 201.75Cr 197.39Cr 8.46TCr | 69Cr 60Cr 57Cr 52Cr 97Cr 6.58TCr 98Cr 681.25Cr 263.86Cr 3.36TCr 257.91Cr 252.33Cr 11TCr |
| Net income | 5.33Cr 4.67Cr 4.41Cr 4.02Cr 7.53Cr 510.55Cr 7.58Cr 53Cr 20Cr 260.83Cr 20Cr 20Cr 838.28Cr | 17Cr 15Cr 14Cr 13Cr 24Cr 1.66TCr 25Cr 171.71Cr 67Cr 847.79Cr 65Cr 64Cr 2.72TCr |
| Net Debt | -29Cr -25Cr -24Cr -22Cr -41Cr -2.76TCr -41Cr -286.01Cr -110.78Cr -1.41TCr -108.28Cr -105.94Cr -4.54TCr | -64Cr -56Cr -53Cr -48Cr -90Cr -6.11TCr -91Cr -632.49Cr -244.97Cr -3.12TCr -239.45Cr -234.27Cr -10TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/26/25 | $26.92 | +2.47% | 20,39,977 |
| 24/26/24 | $26.27 | -0.42% | 21,77,536 |
| 23/26/23 | $26.38 | -5.04% | 25,12,212 |
| 22/26/22 | $27.78 | +7.01% | 28,57,941 |
| 21/26/21 | $25.96 | +2.29% | 18,88,258 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ARQT Stock
Select your edition
All financial news and data tailored to specific country editions
